and note that the scoping study announced lithium oxide and lithium sulphate as options to pursue, but after March 2020, reference to lithium oxide is mysteriously missing, and then, the scoping study is seen as stand alone but while the company gives the study a stand alone treatment, why then is it slipped into the back of the DFS, and then THEN, the public have to wait till the quarterly comes out 3 months later to learn what the issues are.
if you think this is acceptable then as ozblue would say, who are the “company shills” operative here?
FFX Price at posting:
23.0¢ Sentiment: Hold Disclosure: Held